Cingulate(CING) - 2023 Q1 - Quarterly Report

In March 2023, we announced a joint commercialization agreement with Indegene, a comprehensive life sciences commercialization company, to provide commercial support for our lead candidate CTx-1301 (dexmethylphenidate). The agreement spans cross-functional services through an omnichannel marketing approach uniquely designed to successfully manage precommercial support during our Phase 3 clinical trials and to effectively commercialize CTx-1301 nationwide following potential FDA approval. 17 CTx-2103: We hav ...